Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:04 2024-05-21 am EDT 5-day change 1st Jan Change
0.027 AUD +3.85% Intraday chart for Actinogen Medical Limited -6.90% +22.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7% MT
Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer MT
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24% MT
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder CI
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3% MT
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial CI
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16% MT
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation MT
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3% MT
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment MT
Actinogen Medical Activates First Trial Site for Phase 2B Alzheimer’s Disease Trial MT
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial CI
Actinogen Medical's XanaCIDD Trial Enrolment Surpasses 50% Milestone MT
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund MT
Actinogen Medical Names CFO MT
Actinogen Medical Limited Announces CFO Changes CI
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston CI
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug MT
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results CI
Actinogen Medical Completes AU$10 Rights Issue MT
Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Actinogen Medical to Raise AU$10 Million for Clinical Trial Program; Shares Down 22% MT
Companies in Alzheimer's race after US nod for Eisai/Biogen drug RE
Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention CI
Chart Actinogen Medical Limited
More charts
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. It has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The Company conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ACW Stock
  4. News Actinogen Medical Limited
  5. Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW